Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAD-SG: Sacituzumab Govitecan and Adaptive Radiotherapy for Bladder Preservation in MIBC
NCT05833867Phase 1Recruiting
- Start
- Apr 2024
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sacituzumab govitecan in muscle-invasive bladder cancer (MIBC). Primary endpoint: Rate of acute-dose limiting toxicities at 6 months. Started Apr 2024; status: recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT05833867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05833867.